Acute and chronic XXXX of Nigella sativa fixed oil.

@entity8 @entity137 @entity19 @entity412 @entity492 @entity1017 @entity35 @entity493 @entity413 @entity165
We investigated the @entity137 of the fixed oil of Nigella sativa L seeds in @entity19 and @entity35 through determination of LD50 values and examination of possible biochemical, hematological and histopathological changes. The acute @entity137 of Nigella sativa fixed oil was investigated in @entity19 . LD50 values, obtained by single doses, orally and intraperitoneally administered in @entity19 , were 28.8 ml/kg body wt. p.o. [26.2-31.6] and 2.06 ml/kg body wt. i.p. [1.86-2.26], respectively. @entity137 was studied in @entity35 treated daily with an oral dose of 2 ml/kg body wt. for 12 weeks. Changes in key hepatic enzymes levels, including @entity492 -aminotransferase, @entity493 -aminotranferase, and gamma-glutamyltransferase and histopathological modifications (heart, @entity8 ) were not observed in @entity35 treated with Nigella sativa after 12 weeks of treatment. The serum @entity165 , @entity412 and @entity413 levels and the count of leukocytes and platelets decreased significantly, compared to control values, while hematocrit and hemoglobin levels increased significantly. A slowing of body @entity1017 was also observed in Nigella sativa treated @entity35 , as compared to control animals. The low @entity137 of Nigella sativa fixed oil, evidenced by high LD50 values, key hepatic enzyme stability and organ integrity, suggests a wide margin of safety for therapeutic doses of Nigella sativa fixed oil, but the changes in hemoglobin metabolism and the fall in leukocyte and platelet count must be taken into consideration.
